NuMedii applies predictive Big Data and network‑based algorithms—originally developed at Stanford and exclusively licensed to the company—to discover drug‑disease connections and biomarkers. The company translates those predictions into novel therapeutic candidates and has validated its platform with six of six candidates showing preclinical activity for predicted indications. NuMedii plans to use its recent funding to further develop its proprietary technology and prepare its first three internal drug development programs for clinical testing. It pursues capital‑efficient, “digital” pharma development and intends to partner with pharmaceutical companies for development and commercialization. The company has a strategic collaboration with Aptalis Pharma (announced 2012) focused on gastrointestinal disorders and cystic fibrosis. NuMedii has expanded its board and appointed Craig Webb, Ph.D., as Chief Scientific Officer to support translational and clinical work.

Total raised

$4M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2013